Biotechnology

INNOCARE

InnoCare Pharma's ICP-488 Completes First Patient Dosing in Phase II Trial for Cutaneous Lupus

InnoCare's ICP-054 Completes First Patient Enrollment

Nocile Jianhua's TYK2 Inhibitor Approved for Phase II Clinical Trials in Treating Sjogren's Syndrome

Nocia Health's Innovative Drug ICP-B208 Approved for Clinical Trials

NoCamels Completes First Patient Enrollment in Phase III Clinical Trial for Lupus Treatment with Orelabrutinib

Noxiajianhua Releases 2025 ESG Report Showing First Profit and Orelabrutinib's Approval in National Health Insurance Directory

INNOCARE released FY2026 Q1 earnings on April 23 After-Market (BJT), actual revenue HKD 599.32 M (forecast HKD 741.58 M), actual EPS HKD 0.068

INNOCARE to Release FY2026 Q1 Earnings on April 23 After-Market (BJT), Forecast Revenue HKD 741.32 M

Novalgin Pharma Removes Special Identifier, Turns Profit

Goldman Sachs Releases Performance Analysis Report on Novoheart

UBS Cuts 2026 EPS Forecast for Novotech Health Holdings

INNOCARE released FY2025 Annual Earnings on March 25 During-Market (BJT), Actual Revenue HKD 2.596 B (Forecast HKD 2.63 B), Actual EPS HKD 0.4153 (Forecast HKD 0.3996)

INNOCARE released FY2025 Q4 earnings on March 25 During-Market (BJT), actual revenue HKD 1.401 B (forecast HKD 1.389 B), actual EPS HKD 0.4069

INNOCARE to Release FY2025 Earnings on March 25 During-Market (BJT), Forecast Revenue HKD 2.688 B, EPS HKD 0.4084

Nurix's Zurletrectinib Obtains Priority Review Status in China

Nocilehua Completes Mesutoclax and Obetinib Phase III Clinical Trial Patient Enrollment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Nociaojianhua's Self-Developed VAV1 Molecular Glue Degrader ICP-538 Approved for Clinical Trial

Nocilejianhua Completes Phase III Clinical Trial Patient Enrollment for ICP-488 in Psoriasis Treatment

Nociajianhua Expects Net Profit of 633 Million Yuan in 2025, Up 142% YoY

Nocileg Pharma Completes Patient Enrollment for Soficitinib Clinical Trials in AD and Vitiligo

FAMEGLOW

TJCD

ZHONGSHENJIANYE

NEW GONOW RV

ZXZN QI-HOUSE

51WORLD

EASYHOLD GROUP

CH CITY INFRA

INTELLIMARK W27

GREEN BROAD

688428

InnoCare Pharma has received approval from the China National Medical Products Administration to initiate a clinical trial for its novel CDH17 targeted ADC, ICP-B208. This ADC targets CDH17, a protein involved in tumor cell proliferation, and aims to treat gastrointestinal cancers. ICP-B208 is designed to enhance tumor-killing effects and has shown promising preclinical results. This marks a significant milestone for InnoCare's ADC platform, which aims to expand its portfolio of innovative cancer treatments.

GlobeNewswire

InnoCare Pharma

InnoCare Announces Approval of Clinical Trial of Novel CDH7 targeted ADC ICP-B208 in China

09969

588860

516500

520880

159102

520690

159316

159849

159992

588130

516930

159837

516820

InnoCare Pharma announced the first patient has been dosed in a Phase III trial for orelabrutinib, a BTK inhibitor for systemic lupus erythematosus (SLE). This randomized, double-blind study aims to evaluate the drug's efficacy and safety, with a primary endpoint of SRI-4 response rate at Week 52. Orelabrutinib previously met its primary endpoint in a Phase IIb trial, showing significant efficacy. The company aims to accelerate development to address the unmet medical needs of SLE patients, particularly in China, where there are approximately 1 million cases.

ICBCCS SSE STAR Biology and Medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Huaan Hang Seng Biotech ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Penghua SSE STAR Biology and Medicine ETF

China Southern Hang Seng Biotech ETF(QDII)

Tianhong CNI BIOMEDICINE ETF

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund Hang Seng SCHK Innovative Drug ETF

China Merchants CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

E Fund CSI 300 Health Care ETF

Guotai CSI Bio-medicine ETF

Ping An CSI Medicine and Medical Device Innovation ETF

InnoCare Announces First Patient Dosed in Phase III Trial of Orelabrutinib for SLE

159892

513120

InnoCare Pharma (SEHK:9969) has seen a 4.4% share price increase recently, with a mixed performance over the past week, month, and three months. The stock is up 17.6% year-to-date and has a one-year total return of 44.97%. Analysts suggest a fair value of HK$21.27, indicating it is undervalued at the current price of HK$14.70, with a significant intrinsic value gap of 59%. However, there is disagreement among analysts regarding future price targets, ranging from HK$8.2 to HK$25.79, reflecting varying expectations of growth and profitability.

Simplywall

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

A Look At InnoCare Pharma (SEHK:9969) Valuation After Recent Share Price Momentum And Analyst Discount

InnoCare Pharma Ltd. plans to adopt a 2026 RMB Share Incentive Scheme at its upcoming annual general meeting to enhance employee alignment with shareholder interests. The scheme aims to attract key talent and motivate staff. Shareholders will vote on the scheme and its implementation. The company has received a waiver from the Hong Kong Stock Exchange, allowing RMB shares to be issued without requiring a listing in Hong Kong. The latest analyst rating for InnoCare Pharma (HK:9969) is a Buy with a price target of HK$18.31.

Tip Ranks

HKEX

HKEX-R

Hong Kong Exchanges and Clearing (HKEX)

InnoCare Pharma Seeks Approval for 2026 RMB Share Incentive Scheme and Wins HKEX Waiver

BAYRY

513060

The Barbara Ann Karmanos Cancer Institute has expanded access to three innovative radiopharmaceutical therapies—Lutathera, Pluvicto, and Xofigo—across its network in Michigan. These therapies provide targeted treatment options for oncology patients with metastasized diseases. The institute has been a pioneer in theranostics since 2017, offering nearly 850 infusions and utilizing advanced imaging technology to enhance treatment personalization. This expansion aims to improve patient outcomes by making these therapies more accessible to those in Macomb and Ingham Counties.

prnewswire

Bayer

NOVARTIS AG

Menovo

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

Health Care Select Sector SPDR

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

iShares Global Healthcare

VanEck Biotech ETF

Penghua CSI HK Connect Health Care Composite ETF

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

VG Health

ALPS Medical Breakthrough

Bosera Hang Seng Health Care ETF(QDII)

Ark Genomic Revolution ETF

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

iShares US Pharma

06:42 ETKarmanos Cancer Institute Expands Targeted Radiopharmaceutical Therapies to Additional Cancer Centers

01276

600276

02196

01858

688236

600196

Over half of listed Chinese drugmakers reported increased net profits for 2025, driven by innovative medicines and overseas business. Notable performers include Hengrui Pharmaceuticals, with a 22% profit rise to CNY7.7 billion, and InnoCare Pharma, achieving its first profit of CNY642 million. Fosun Pharmaceutical Group's net profit rose 22% to CNY3.4 billion, while Chunlizhengda Medical Instruments saw a 118% profit surge. The industry is focusing on innovative R&D and adapting to evolving consumer demands, with firms emphasizing integration of online and offline services.

Yicai

HENGRUI PHARMA

Hengrui Pharma

FOSUN PHARMA

CHUNLI MEDICAL

Chunli Medical

Over Half of Listed Chinese Drugmakers See 2025 Profit Grow Buoyed by Innovative Medicines, Overseas Business

InnoCare Pharma Co., Ltd. released its financial report for the period ending December 31, 2025, with revenue of 2.375 billion yuan and a net profit of 642 million yuan, a significant improvement compared to a net loss of 441 million yuan in the same period last year. The increase in drug sales revenue is mainly attributed to the rise in sales of Orelabrutinib and Tanshinone IIA. King Bridge may have fully liquidated its position, cashing out approximately 2 billion yuan

雷帝触网

InnoCare Pharma annual revenue of 2.4 billion: net profit of 640 million, King Bridge liquidates or cashes out 2 billion

InnoCare Pharma has achieved profitability, marking the company's entry into a new development stage. The company's annual profit reached 644 million yuan, achieving profitability two years ahead of the original plan, with significant breakthroughs in global layout. The valuation of the company's H shares is only half of that of A shares, indicating upward potential. The 2025 annual report shows a revenue surge of 135% to 2.38 billion yuan, with a significant turning point in profitability, transforming into an entity focused on endogenous development. Profitability is driven by a dual engine of external licensing and product sales, with drug sales reaching 1.44 billion yuan, a year-on-year increase of 43.4%

BambooWorks

InnoCare Pharma achieves profitability milestone, driven by globalization and a strong pipeline for new development

INNOCARE(09969.HK)